nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2021-8-4-103-104nodgo-778Research ArticleРЕЗОЛЮЦИИRESOLUTIONSРезолюция Совета экспертов «Роль препарата руриоктоког альфа пэгол в лечении пациентов с гемофилией А»Resolution of the Council of Experts “The role of the drug rurioctocog alfa pegol in the treatment of patients with hemophilia A”РедакционнаястатьяEditorialArticle20212001202284103104Copyright © Редакционная с., 20222022Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/778
.
.
ReferencesИнструкция по медицинскому применению препарата Аденовейт®. [Электронный ресурс]: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=45878db3-0e74-4584-9bddd772e10a5557&t= (дата обращения 07.09.2021).Instructions for medical use of the drug Adenovate®. [Electronic resource]: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=45878db3-0e74-4584-9bdd-d772e10a5557&t= (appeal date 07.09.2021). (In Russ.).Konkle B.A., Stasyshyn O., Chowdary P., Bevan D.H., Mant T., Shima M., Engl W., Dyck-Jones J., Fuerlinger M., Patrone L., Ewenstein B., Abbuehl B. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078–85. doi:10.1182/blood-2015-03-630897.Konkle B.A., Stasyshyn O., Chowdary P., Bevan D.H., Mant T., Shima M., Engl W., Dyck-Jones J., Fuerlinger M., Patrone L., Ewenstein B., Abbuehl B. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078–85. doi:10.1182/blood-2015-03-630897.Mullins E.S., Stasyshyn O., Alvarez-Roman M.T., Osman D., Liesner R., Engl W., Sharkhawy M., Abbuehl B.E. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017;23(2):238–46. doi:10.1111/hae.13119.Mullins E.S., Stasyshyn O., Alvarez-Roman M.T., Osman D., Liesner R., Engl W., Sharkhawy M., Abbuehl B.E. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2017;23(2):238–46. doi:10.1111/hae.13119.Booth J. et al. EAHAD, Paris, France, 2017; Poster P078.Booth J. et al. EAHAD, Paris, France, 2017; Poster P078.Chowdary P., Mullins E.S., Konkle B.A., McGuinn C., Park Y.S., Stasyshyn O., Zulfikar B., Engl W., Tangada S. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia. 2020;26:e168–e78. doi:10.1111/hae.14052.Chowdary P., Mullins E.S., Konkle B.A., McGuinn C., Park Y.S., Stasyshyn O., Zulfikar B., Engl W., Tangada S. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia. 2020;26:e168–e78. doi:10.1111/hae.14052.Klamroth R., Windyga J., Radulescu V., Collins P.W., Stasyshyn O., Ibrahim H.M., Engl W., Tangada S.D., Savage W., Ewenstein B. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. Blood. 2021;137(13):1818–27. doi:10.1182/blood.2020005673.Klamroth R., Windyga J., Radulescu V., Collins P.W., Stasyshyn O., Ibrahim H.M., Engl W., Tangada S.D., Savage W., Ewenstein B. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study. Blood. 2021;137(13):1818–27. doi:10.1182/blood.2020005673.
The authors declare that there are no conflicts of interest present.